Tocilizumab for Relapsing Polychondritis
Information source: McMaster Children's Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Relapsing Polychondritis
Intervention: Tocilizumab (Drug)
Phase: Phase 2
Status: Withdrawn
Sponsored by: McMaster Children's Hospital Official(s) and/or principal investigator(s): Maggie Larché, MD, PhD, Principal Investigator, Affiliation: McMaster University and Children's Hospital
Summary
This is a study for one patient with severe relapsing polychondritis which has been
unresponsive to other more conventional medications including prednisone, methotrexate,
anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be
monitored by clinical assessment and bloodwork.
Clinical Details
Official title: Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Efficacy of Tocilizumab
Secondary outcome: Safety of Tocilizumab
Eligibility
Minimum age: 12 Years.
Maximum age: 15 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- A single patient with unremitting inflammatory relapsing polychondritis
Exclusion Criteria:
- As this is a study in a single patient, there are no exclusions
Locations and Contacts
McMaster Children's Hospital, Hamilton, Ontario L8N 3YZ, Canada
Additional Information
Starting date: May 2010
Last updated: May 12, 2014
|